There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people with OSA don't sleep well, they are at a higher risk for motor vehicle ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Researchers combine OCT imaging and computational fluid dynamics to accurately map upper airway obstructions, advancing sleep ...

Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive ...

The likelihood for obstructive sleep apnea went down by 74% among adults with optimal vs. insufficient healthy lifestyle ...

Discover the evolving landscape of wellness in India, from traditional practices to specialized programs addressing modern ...

Do you experience an inclination for snoring, daytime sleepiness, obesity, high blood pressure, impaired concentration and ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

NObesity, a well-known weight loss clinic specializing in state-of-the-art bariatric surgery, has successfully performed a life-changing procedure on 61-year-old Jayeshkumar Jani, marking a ...

(HealthDay News) — The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA). In a news ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.The medicine, part of the class known as GLP-1 ...